Drugs / HUMAN INSULIN (BIOSYNTHETIC)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01194882 | Nov 2010 → Feb 2018 | type 1 diabetes mellitus | Sanofi | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HUMAN INSULIN (BIOSYNTHETIC) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01194882 ↗ |
| Known as | Insuman implantable | “Insuman implantable(®) (400 IU/mL) (Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany), a recombinant human insulin, has been developed as a replacement for Insuplant(®)” PMID 24735100 ↗ Apr 2014 |
| Modality | Protein / enzyme biologic | “a recombinant human insulin” PMID 24735100 ↗ Apr 2014 |
| Route | Other | “Route of administration: Intraperitoneal use” NCT01194882 ↗ |